Life sciences briefing: Tuesday, Sept. 11, 2007
Featured companies: Enobia, F-star, N Spine, Omni Life Science
Enobia splints together $38M for bone disorders — Montreal’s Enobia, a biotech focused on aiming drugs specifically at bone diseases, raised C$40.1 million ($38 million) in a second funding round. Investors included OrbiMed Advisors, CTI Life Sciences Fund, the Fonds de solidarite FTQ, Desjardins Venture Capital, Lothian Partners and T2C2/Bio 2000.
Enobia intends to deliver bone-related drugs directly to bone tissue in order to reduce both dosages and possible… Continue Reading